Skip to main content

Full Schedule

Full Schedule

  • Friday, March 25, 2022
  • 8:00 AM – 10:00 AM
    I - Session I: Updates in Gastroesophageal Junction Cancer
    Talks within this session are supported by an educational grant provided by Astellas.
  • 10:00 AM – 11:00 AM
    Winning the Debate: Can ctDNA Help Predict Adjuvant Treatment Benefit?
  • 11:00 AM – 12:00 PM
    II - Session II: Current Developments in Colorectal Cancer
  • 12:00 PM – 1:00 PM
    Non-CME Innovation Theater
  • 1:00 PM – 3:10 PM
    III - Session III: Current Challenges in Colorectal Cancer
  • 3:10 PM – 3:30 PM
    Break
  • 3:30 PM – 5:50 PM
    IV - Session IV: Trending Topics in Colorectal Cancer
  • Saturday, March 26, 2022
  • 8:30 AM – 10:00 AM
    V - Session V: Pancreatic Cancer
  • 10:00 AM – 11:00 AM
    Non-CME Innovation Theater
  • 11:00 AM – 1:00 PM
    VI - Session VI: Hepatobiliary Cancers
    Talks within this session are supported by an educational grant provided by AstraZeneca and Genentech.
  • 1:00 PM – 2:00 PM
    A Treatment Option for Certain Patients with Advanced Gastric or GEJ Cancer
  • 2:00 PM – 3:00 PM
    VII - Session VII: Emerging Treatment Approaches for Esophagogastric Cancer
  • 3:00 PM – 3:20 PM
    Break
  • 3:20 PM – 4:30 PM
    VIII - Session VIII: Management of Uncommon Tumors
  • Wednesday, April 20, 2022
  • 9:00 AM – 10:10 AM
    I - Session I: Current Developments in Colorectal Cancer
  • 10:10 AM – 10:20 AM
    Break
  • 10:20 AM – 11:20 AM
    Non-CME Innovation Theater
  • 11:20 AM – 11:30 AM
    Break
  • 11:30 AM – 1:40 PM
    II - Session II: Trending Topics in Colorectal Cancer
  • 1:40 PM – 2:00 PM
    Break
  • 2:00 PM – 4:00 PM
    III - Session III: Current Challenges in Colorectal Cancer
  • Thursday, April 21, 2022
  • 9:50 AM – 11:50 AM
    IV - Session IV: Updates in Gastroesophageal Junction Cancer
    Talks within this session are supported by an educational grant provided by Astellas
  • 11:50 AM – 12:10 PM
    Break
  • 12:10 PM – 1:30 PM
    V - Session V: Pancreatic Cancer
  • 1:30 PM – 1:50 PM
    Break
  • 1:50 PM – 4:00 PM
    VI - Session VI: Hepatobiliary Cancers
    Talks within this session are supported by an educational grant provided by AstraZeneca
  • Friday, April 22, 2022
  • 9:00 AM – 10:10 AM
    VII - Session VII: Emerging Treatment Approaches for Esophagogastric Cancer
  • 10:10 AM – 10:30 AM
    Break
  • 10:30 AM – 11:50 AM
    VIII - Session VIII: Management of Uncommon Tumors
  • 11:50 AM – 12:10 PM
    Break
  • 12:10 PM – 2:00 PM
    IX - Session IX: Special Topics - Current Progress in GI Cancer Prevention
  • Wednesday, August 10, 2022
  • 9:00 AM – 10:40 AM
    I - Session I: Current Developments in Colorectal Cancer
  • 10:40 AM – 11:00 AM
    Break
  • 11:00 AM – 12:55 PM
    II - Session II: Trending Topics in Colorectal Cancer
  • 12:55 PM – 1:15 PM
    Break
  • 1:15 PM – 3:10 PM
    III - Session III: Current Challenges in Colorectal Cancer
  • Thursday, August 11, 2022
  • 9:00 AM – 11:10 AM
    IV - Session IV: Updates in Gastroesophageal Junction Cancer
    Talks within this session are supported by an educational grant provided by Astellas and Seagen Inc.
  • 11:10 AM – 11:30 AM
    Break
  • 11:30 AM – 12:55 PM
    V - Session V: Pancreatic Cancer
  • 12:55 PM – 1:15 PM
    Break
  • 1:15 PM – 4:00 PM
    VI - Session VI: Hepatobiliary Cancers
    Talks within this session are supported by an educational grant provided by Seagen Inc.
  • Friday, August 12, 2022
  • 9:00 AM – 10:45 AM
    VII - Session VII: Emerging Treatment Approaches for Esophagogastric Cancer
  • 10:45 AM – 11:05 AM
    Break
  • 11:05 AM – 12:40 PM
    VIII - Session VIII: Management of Uncommon Tumors
  • 12:40 PM – 1:00 PM
    Break
  • 1:00 PM – 2:35 PM
    IX - Session IX: Special Topics – Palliative Care, Genetic Testing, and Complementary Medicine in GI Cancers
  • Wednesday, September 21, 2022
  • 8:00 AM – 10:25 AM
    I - Session I: Current Developments in Colorectal Cancer
  • 10:25 AM – 10:35 AM
    Exhibit Hall
  • 10:35 AM – 11:35 AM
    Non-CME Innovation Theater
  • 11:35 AM – 11:45 AM
    Exhibit Hall
  • 11:45 AM – 1:00 PM
    II - Session II: Trending Topics in Colorectal Cancer
  • 1:00 PM – 1:10 PM
    Exhibit Hall
  • 1:10 PM – 2:10 PM
    Non-CME Innovation Theater
  • 2:10 PM – 2:20 PM
    Exhibit Hall
  • 2:20 PM – 3:55 PM
    III - Session III: Current Challenges in Colorectal Cancer
  • Thursday, September 22, 2022
  • 8:00 AM – 10:15 AM
    IV - Session IV: Updates in Gastroesophageal Junction Cancer
    Talks within this session are supported by an educational grant provided by Seagen Inc.
  • 10:15 AM – 10:25 AM
    Exhibit Hall
  • 10:25 AM – 11:25 AM
    Non-CME Innovation Theater
  • 11:25 AM – 11:35 AM
    Exhibit Hall
  • 11:35 AM – 1:00 PM
    V - Session V: Pancreatic Cancer
  • 1:00 PM – 1:30 PM
    Exhibit Hall
  • 1:30 PM – 4:15 PM
    VI - Session VI: Hepatobiliary Cancers
  • Friday, September 23, 2022
  • 8:00 AM – 9:45 AM
    VII - Session VII: Emerging Treatment Approaches for Esophagogastric Cancer
  • 9:45 AM – 10:15 AM
    Exhibit Hall
  • 10:15 AM – 12:10 PM
    VIII - Session VIII: Management of Uncommon Tumors
  • 12:10 PM – 12:40 PM
    Exhibit Hall
  • 12:40 PM – 2:15 PM
    IX - Session IX: Special Topics – Genetic Testing, Early Onset Cancers, and Reconciling Treatment Guidelines
  • Wednesday, November 16, 2022
  • 9:00 AM – 11:25 AM
    I - Session I: Current Developments in Colorectal Cancer
  • 11:25 AM – 11:35 AM
    Exhibit Hall
  • 11:35 AM – 12:35 PM
    A Treatment Option for Certain Patients with Advanced Esophageal Cancer – Webcast: John L. Marshall, MD
  • 12:35 PM – 12:45 PM
    Exhibit Hall
  • 12:45 PM – 2:20 PM
    II - Session II: Trending Topics in Colorectal Cancer
  • 2:20 PM – 2:50 PM
    Exhibit Hall
  • 2:50 PM – 4:25 PM
    III - Session III: Current Challenges in Colorectal Cancer
  • Thursday, November 17, 2022
  • 9:00 AM – 11:15 AM
    IV - Session IV: Updates in Gastroesophageal Junction Cancer
  • 11:15 AM – 11:25 AM
    Exhibit Hall
  • 11:25 AM – 12:25 PM
    Newly Approved Treatment Option for Unresectable Hepatocellular Carcinoma - Michael Morse, MD
  • 12:25 PM – 12:35 PM
    Exhibit Hall
  • 12:35 PM – 2:00 PM
    V - Session V: Pancreatic Cancer
  • 2:00 PM – 2:30 PM
    Exhibit Hall
  • 2:30 PM – 4:45 PM
    VI - Session VI: Hepatobiliary Cancers
  • Friday, November 18, 2022
  • 9:00 AM – 10:15 AM
    VII - Session VII: Emerging Treatment Approaches for Esophagogastric Cancer
  • 10:15 AM – 10:45 AM
    Exhibit Hall
  • 10:45 AM – 12:40 PM
    VIII - Session VIII: Management of Uncommon Tumors
  • 12:40 PM – 1:10 PM
    Exhibit Hall
  • 1:10 PM – 3:15 PM
    IX - Session IX: Special Topics – Genetic Testing, Supportive Care, and Complementary Therapies to Optimize Clincial Care